Bioavailability of Once- and Twice-Daily Regimens of Didanosine in Human Immunodeficiency Virus-Infected Children

AUTOR(ES)

Abreu, Thalita

FONTE

American Society for Microbiology

RESUMO

The bioavailability of didanosine at 180 mg/m2 once daily was compared to that at 90 mg/m2 twice daily in 24 children with advanced human immunodeficiency virus infection. Children were studied at steady state using optimal sampling and prior pharmacokinetic parameter estimates. Relative bioavailability was 0.95 ± 0.49, supporting the potential clinical adequacy of once-daily dosing.

Documentos Relacionados

• Once-daily versus twice-daily administration of ceftazidime in the preterm infant.
• Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.
• Comparison of Once-Daily versus Twice-Daily Administration of Cefdinir against Typical Bacterial Respiratory Tract Pathogens
• Pharmacokinetics of Dapsone Administered Daily and Weekly in Human Immunodeficiency Virus-Infected Children
• Pharmacologic Characteristics of Indinavir, Didanosine, and Stavudine in Human Immunodeficiency Virus-Infected Children Receiving Combination Therapy